Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Payables (2016 - 2025)

Amicus Therapeutics' Payables history spans 16 years, with the latest figure at $28.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 121.13% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, up 121.13%, and an annual FY2025 reading of $28.6 million, up 121.13% over the prior year.
  • Payables for Q4 2025 was $28.6 million at Amicus Therapeutics, up from $19.1 million in the prior quarter.
  • The five-year high for Payables was $32.1 million in Q2 2024, with the low at $9.2 million in Q1 2024.
  • Average Payables over 5 years is $18.5 million, with a median of $15.8 million recorded in 2021.
  • Biggest YoY gain for Payables was 137.07% in 2024; the steepest drop was 63.11% in 2024.
  • Tracing FOLD's Payables over 5 years: stood at $21.5 million in 2021, then decreased by 28.35% to $15.4 million in 2022, then fell by 1.9% to $15.1 million in 2023, then decreased by 14.37% to $12.9 million in 2024, then soared by 121.13% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Payables are $28.6 million (Q4 2025), $19.1 million (Q3 2025), and $13.9 million (Q2 2025).